| Literature DB >> 34058388 |
Emily A Voigt1, Jasmine Fuerte-Stone2, Brian Granger2, Jacob Archer2, Neal Van Hoeven3.
Abstract
We present a live-attenuated RNA hybrid vaccine technology that uses an RNA vaccine delivery vehicle to deliver in vitro-transcribed, full-length, live-attenuated viral genomes to the site of vaccination. This technology allows ready manufacturing in a cell-free environment, regardless of viral attenuation level, and it promises to avoid many safety and manufacturing challenges of traditional live-attenuated vaccines. We demonstrate this technology through development and testing of a live-attenuated RNA hybrid vaccine against Chikungunya virus (CHIKV), comprised of an in vitro-transcribed, highly attenuated CHIKV genome delivered by a highly stable nanostructured lipid carrier (NLC) formulation as an intramuscular injection. We demonstrate that single-dose immunization of immunocompetent C57BL/6 mice results in induction of high CHIKV-neutralizing antibody titers and protection against mortality and footpad swelling after lethal CHIKV challenge.Entities:
Keywords: Chikungunya; RNA vaccine; arthritis; hybrid vaccine; infection; live-attenuated; nanostructured lipid carrier; viral vaccine; virus
Mesh：
Substances：
Year: 2021 PMID： 34058388 PMCID： PMC8417506 DOI： 10.1016/j.ymthe.2021.05.018
Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 12.910